Eversept Partners LP decreased its holdings in shares of Danaher Co. (NYSE:DHR) by 8.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 145,104 shares of the conglomerate’s stock after selling 13,660 shares during the quarter. Danaher comprises approximately 5.9% of Eversept Partners LP’s holdings, making the stock its 5th largest position. Eversept Partners LP’s holdings in Danaher were worth $20,761,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the stock. Next Capital Management LLC acquired a new position in Danaher in the 2nd quarter valued at approximately $31,000. Litman Gregory Asset Management LLC acquired a new position in Danaher in the 2nd quarter valued at approximately $33,000. Altshuler Shaham Ltd raised its holdings in Danaher by 59.3% in the 2nd quarter. Altshuler Shaham Ltd now owns 239 shares of the conglomerate’s stock valued at $34,000 after acquiring an additional 89 shares in the last quarter. MRA Associates USA LLC acquired a new position in Danaher in the 2nd quarter valued at approximately $40,000. Finally, Lenox Wealth Management Inc. acquired a new position in Danaher in the 1st quarter valued at approximately $40,000. Hedge funds and other institutional investors own 78.52% of the company’s stock.
In related news, insider Thomas Patrick Joyce, Jr. sold 70,544 shares of the firm’s stock in a transaction on Friday, July 19th. The stock was sold at an average price of $141.77, for a total transaction of $10,001,022.88. Following the completion of the sale, the insider now directly owns 271,023 shares of the company’s stock, valued at approximately $38,422,930.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Mitchell P. Rales purchased 2,500 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were acquired at an average cost of $139.52 per share, with a total value of $348,800.00. Following the completion of the acquisition, the chairman now directly owns 3,030,453 shares in the company, valued at $422,808,802.56. The disclosure for this purchase can be found here. Over the last three months, insiders sold 177,202 shares of company stock valued at $25,175,829. 11.40% of the stock is currently owned by insiders.
Shares of DHR traded up $0.59 during mid-day trading on Friday, reaching $142.33. The company had a trading volume of 13,457 shares, compared to its average volume of 1,917,615. Danaher Co. has a twelve month low of $94.59 and a twelve month high of $145.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.32 and a quick ratio of 1.91. The company’s 50-day moving average is $140.18 and its 200-day moving average is $135.10. The company has a market capitalization of $97.99 billion, a P/E ratio of 31.50, a P/E/G ratio of 2.46 and a beta of 0.94.
Danaher (NYSE:DHR) last issued its earnings results on Thursday, July 18th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.15 by $0.04. Danaher had a return on equity of 11.53% and a net margin of 12.22%. The business had revenue of $5.16 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the prior year, the firm posted $1.15 EPS. Danaher’s quarterly revenue was up 3.5% compared to the same quarter last year. As a group, equities analysts expect that Danaher Co. will post 4.79 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.17 dividend. The ex-dividend date of this dividend is Thursday, September 26th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.48%. Danaher’s payout ratio is presently 15.04%.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Recommended Story: The limitations of an equal weight rating
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.